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Abstract 32 
Thiamine-coated nanoparticles were prepared by two different preparative methods 33 
and evaluated to compare their mucus-penetrating properties and fate in vivo. The first 34 
method of preparation consisted of surface modification of freshly poly(anhydride) 35 
nanoparticles (NP) by simple incubation with thiamine (T-NPA). The second procedure 36 
focused on the preparation and characterization of a new polymeric conjugate between 37 
the poly(anhydride) backbone and thiamine prior the nanoparticle formation (T-NPB). 38 
The resulting nanoparticles displayed comparable sizes (about 200 nm) and slightly 39 
negative surface charges. For T-NPA, the amount of thiamine associated to the surface 40 
of the nanoparticles was 15 µg/mg. For in vivo studies, nanoparticles were labeled with 41 
either 99mTc or Lumogen® Red. T-NPA and T-NPB moved faster from the stomach to the 42 
small intestine than naked nanoparticles. Two hours post-administration, for T-NPA and 43 
T-NPB, more than 30% of the given dose was found in close contact with the intestinal 44 
mucosa, compared with a 13.5% for NP. Interestingly, both types of thiamine-coated 45 
nanoparticles showed a greater ability to cross the mucus layer and interact with the 46 
surface of the intestinal epithelium than NP, which remained adhered in the mucus 47 
layer. Four hours post-administration, around 35% of T-NPA and T-NPB were localized 48 
in the ileum of animals. Overall, both preparative processes yielded thiamine decorated 49 
carriers with similar physico-chemical and biodistribution properties, increasing the 50 
versatility of these nanocarriers as oral delivery systems for a number of biologically 51 
active compounds.  52 
 53 
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1. Introduction 58 
The oral route is, in general, perceived by patients as more comfortable and convenient 59 
than other routes of drug administration, especially for chronic medication regimens. 60 
However, the oral route remains an important challenge that limits the absorption and 61 
bioavailability of many biologically active compounds, especially for therapeutic 62 
peptides and proteins as well as for drugs suffering from presystemic metabolism. From 63 
a biological point of view, the oral delivery of drugs is faced with several main barriers: 64 
(i) the acidic pH environment in the stomach, (ii) the enzymatic activity along the gut, 65 
(iii) the protective mucus gel layer, (iv) the unstirred water layer adjacent to the 66 
epithelium and (v) the surface of absorptive cells, including the glycocalyx. All of these 67 
barriers limit the arrival of the unchanged biologically active compound to the portal 68 
and/or the systemic circulation (Netsomboon and Bernkop-Schnürch, 2016; Schulz et 69 
al., 2015).  70 
In order to overcome these hurdles, different delivery systems have been proposed and 71 
are currently under evaluation, including the use of polymer nanoparticles. In principle, 72 
some of these delivery systems (acting as nanocarriers) may minimize the effects of 73 
extreme pH conditions and digestive enzymes on the stability of the loaded compound, 74 
offering significant increases in the oral bioavailability of some drugs (des Rieux et al., 75 
2006; Roger et al., 2010). However, polymer nanoparticles encounter a formidable 76 
barrier that significantly limits their arrival at the intestinal epithelium, namely the 77 
protective mucus layer lining the epithelium surface of the gut. Thus, most types of these 78 
nanoparticles are efficiently trapped in the mucus layer and, then, rapidly eliminated 79 
from the mucosa due to the physiological mucus turn-over (Inchaurraga et al., 2015; Suk 80 
et al., 2009). In fact, mucus is continuously secreted both to remove pathogens and to 81 
lubricate the epithelium as material passes through (Ensign et al., 2012; Pelaseyed et al., 82 
2014).  83 
In order to address this fundamental limitation, an encouraging strategy would be the 84 
use of nanoparticles with mucus permeating properties. For this purpose, different 85 
strategies have been proposed, including the use of agents to minimize the interaction 86 
of nanocarriers with the mucus layer and the application of bio-inspired procedures 87 
mimicking key features of microorganisms. Thus, the fluidity of mucus and, hence, the 88 
diffusion of nanoparticles through the mucus layer may be increased by either the co-89 
encapsulation of mucolytic agents (e.g., N-acetyl cysteine) (Bourganis et al., 2015) or the 90 
binding of proteolytic enzymes (e.g., papain or bromelain) to the surface of nanocarriers 91 
in order to cleave locally the glycoprotein substructures of mucus (Pereira de Sousa et 92 
al., 2015a). A second interesting approach would be the use of biomimetic strategies, in 93 
line with those developed by microorganisms to avoid the protective mucus layer and 94 
facilitate its arrival to the intestinal epithelium before invasion and colonization. Within 95 
this scenario, virus-mimicking nanoparticles presenting both a hydrophilic shell and a 96 
high densely charged surface have been proposed (Pereira de Sousa et al., 2015b). 97 
Similarly, the coating of nanoparticles with either bacterial lipopolysaccharide (Gómez 98 
et al., 2007) or flagellin from Salmonella enteritidis (Salman et al., 2005) was found 99 
adequate to specifically target the intestinal epithelium. A further set of strategies 100 
would involve the decoration of nanoparticles with hydrophilic ligands in order to 101 
minimize the potential hydrophobic interactions of the particles with mucin fibers and 102 
other components of the mucus. These “slippery” nanoparticles can be obtained by 103 
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using poly(ethylene glycol)s (Iglesias et al., 2017; Laffleur et al., 2014; Zabaleta et al., 104 
2012), mannose (Salman et al., 2006) or thiamine (Salman et al., 2007). 105 
However, one key aspect that sometimes is forgotten during the development and 106 
characterization of nanocarriers for mucosal delivery is the combination of the adequate 107 
biodistribution properties (including the ability as mucus permeating devices) with a 108 
high payload capability. In fact, the encapsulation of a biologically active molecule may 109 
significantly modify the physico-chemical properties of empty nanoparticles (Singh and 110 
Lillard, 2009) and, hence, negatively affect their ability to reach the epithelium. This fact 111 
may limit the potential use of such nanoparticles for delivery purposes. In order to 112 
overcome this risk, one possible solution is to develop alternative preparative processes 113 
of nanocarriers that are more adapted to the encapsulation of particular groups of 114 
drugs, without affecting their biodistribution and fate. In this context, the aim of this 115 
work was to prepare thiamine-coated nanoparticles by two different preparative 116 
processes and, then, evaluate and compare their mucus permeating properties and 117 
behavior in vivo.  118 
 119 
2. Materials and Methods  120 
2.1. Materials 121 
The copolymer of methyl vinyl ether and maleic anhydride or poly(anhydride) (Gantrez® 122 
AN 119; MW: 95.5 kDa when calculated by SEC-MALLS) was supplied by Ashland Inc. 123 
(Barcelona, Spain). Thiamine hydrochloride (≥99 %), lactose and calcium chloride were 124 
purchased from Sigma-Aldrich (Madrid, Spain). Di-sodium hydrogen phosphate 125 
anhydrous and ethanol were provided by Panreac (Barcelona, Spain). Perylene-Red 126 
(BASF Lumogen® F Red 305) was from Kremer Pigmente GmbH & Co. (Aichstetten, 127 
Germany) and OCTTM Compound Tissue-Tek from Sakura Finetek Europe (Alphen aan 128 
Der Rijn, The Netherlands).99Mo-99mTc generator was purchased from DRYTEC™ (GE 129 
Healthcare Bio-science, UK). 4’,6-diamidino-2-phenylindole (DAPI) was obtained from  130 
Biotium Inc. (Madrid, Spain). Acetone was from (VWR-Prolabo, Linars del Vallès, Spain) 131 
and sodium hydroxide and isopropanol from Merck (Madrid, Spain). Deionized water 132 
(18.2 MΩ) was prepared by a water purification system (Wasserlab, Pamplona, Spain) 133 
and used to prepare all the solutions. The anesthetic isoflurane (Isoflo™) was from 134 
Esteve, (Barcelona, Spain). All other chemicals and solvents were of analytical grade. 135 
 136 
2.2. Synthesis of the Gantrez® AN-thiamine conjugate (GT) 137 
GT conjugate was obtained by the covalent binding of thiamine to the poly(anhydride) 138 
backbone (Figure 1). For this purpose, 5 g Gantrez® AN were dissolved in 200 mL acetone. 139 
Then, 125 mg thiamine were added and the mixture was heated at 50°C, under magnetic 140 
agitation at 400 rpm, for 3 h. Then, the mixture was filtered through a pleated filter 141 
paper and the organic solvent was eliminated under reduced pressure in a Büchi R-144 142 
apparatus (BÜCHI Labortechnik AG, Flawil, Switzerland) until the conjugate was totally 143 
dry. By gravimetry, the water content was calculated to be 2.9%. 144 
 145 
2.3. Characterization of Gantrez® AN-thiamine conjugate (GT)  146 
The covalent insertion of thiamine in the polymer chain was confirmed by infrared, 147 
elemental and titration analysis. The amount of thiamine bound to the poly(anhydride) 148 
was estimated by HPLC analysis. 149 
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2.3.1 FT-IR analysis 150 
The binding between the poly(anhydride) and thiamine was determined by Fourier 151 
transform infrared spectroscopy (FTIR). Spectra were collected in a Nicolet-FTIR Avatar 152 
360 spectrometer (Thermo/Nicolet 360 FT IR E.S.P.; Thermo Fisher Scientific, Waltham, 153 
Massachusetts, USA), using a MKII Golden Gate ATR device with resolution of 2 cm-1 154 
connected with OMNIC E.S.P. software (Thermo Fisher Scientific, Waltham, 155 
Massachusetts, USA). The spectrum obtained was an average of 32 scans.   156 
2.3.2. Elemental analysis 157 
The C, H, O and N contents of the synthesized conjugates were determined in a LECO 158 
CHN-900 apparatus (Michigan, USA). For this purpose, 1 mg of each polymer was 159 
analyzed by triplicate and the results were expressed as percentage (%w/w). 160 
2.3.3 Titration 161 
The poly(anhydride) and its conjugate were first hydrated and dispersed in water till 162 
their total solubilisation. At this moment the aqueous solutions of the polymers were 163 
titrated with NaOH 0.2 N in the presence of phenolphthalein, used as indicator. Titration 164 
was used to measure the percentage of free carboxylic groups and calculate the degree 165 
of substitution (DS) of the resulting conjugate. The decrease of the carboxylic groups in 166 
the polymer conjugates in comparison to unmodified Gantrez® AN evidenced the ligand 167 
binding. 168 
2.3.4 Thiamine quantification 169 
The amount of thiamine covalently attached to the poly(anhydride) was calculated by a 170 
modification  of a chromatographic method previously described (Salman et al., 2007). 171 
For this purpose, 400 mg Gantrez® AN and 10 mg of thiamine were added to 20 mL 172 
acetone. The mixture was heated at 50°C, under magnetic agitation at 400 rpm, for 3 h.  173 
The organic solvent was eliminated under reduced pressure in a Büchi R-144 apparatus 174 
(BÜCHI Labortechnik AG, Flawil, Switzerland) until the conjugate was totally dry. Once 175 
dried, the resulting unpurified conjugate was dissolved in 20 mL of acetone. Then, 40 176 
mL of deionized water were added until the formation of suspension. This suspension 177 
was centrifuged for 20 minutes at 41,410 x g and the supernatants were collected for 178 
the quantification of thiamine. The analysis was performed in a model 1100 series LC 179 
Agilent (Waldbornn, Germany) coupled with a UV diode array detection system. Data 180 
were analyzed using the Chem-Station G2171 program. The separation of thiamine was 181 
carried out at 40°C on a reversed-phase Zorbax®70Å NH2 column (4.6 × 150 mm; particle 182 
size 5 µm) with a Zorbax® original 70Å NH2 guard column (4.6 x 12.5 mm; particle size 5 183 
µm) obtained from Agilent (Waldbornn, Germany). The mobile phase and samples were 184 
filtered through a Millipore membrane filter of 0.45 µm. The mobile phase composition 185 
was potassium phosphate buffer 50 mM (pH 6) and methanol (80/20, v/v). The flow rate 186 
was set to 1 mL/min and the effluent was monitored with UV detection at 254 nm. 187 
Standard curves were designed over the range of 10-600 µg/mL (R2≥0.999) from a 188 
thiamine solution in deionized water. Finally, the amount of thiamine associated to the 189 
poly(anhydride) backbone was calculated as the difference between the initial amount 190 
of thiamine added and the amount of thiamine recovered in the supernatants. 191 
 192 
2.4. Preparation of thiamine-coated nanoparticles 193 
Thiamine-coated nanoparticles were prepared from two different experimental 194 
procedures.  195 
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The first one consisted on the incubation of “naked” Gantrez® AN nanoparticles and 196 
thiamine following a protocol described previously (Salman et al., 2007) with minor 197 
modifications. Briefly, 400 mg Gantrez® AN were dissolved in 20 mL acetone. Then, the 198 
nanoparticles were formed by the addition of 40 mL absolute ethanol and 40 mL of 199 
distilled water containing 10 mg thiamine. The organic solvents were eliminated under 200 
reduced pressure in a BÜCHI R-144 apparatus (BÜCHI Labortechnik AG, Flawil, 201 
Switzerland) and the resulting nanoparticles were agitated under magnetic stirring for 202 
30 min, at room temperature. Then, the nanoparticles suspensions were purified by 203 
centrifugation at 5000 × g for 20 min (SIGMA Lab. centrifuges, Osterode am Harz, 204 
Germany) using dialysis tubes Vivaspin® 300,000 MWCO (Sartorius AG, Madrid, Spain). 205 
Finally, 800 mg lactose dissolved in 40 mL deionized water was added to the pellet and 206 
vortexed for 5 minutes. The resulting suspension of nanoparticles was dried in a Büchi 207 
Mini Spray Drier B-290 apparatus (BÜCHI Labortechnik AG, Flawil, Switzerland) under 208 
the following experimental conditions: inlet temperature of 90 °C, outlet temperature 209 
of 60 °C, spray-flow of 600 L/h, and aspirator at 100% of the maximum capacity. These 210 
nanoparticles were named T-NPA.  211 
As control, “naked” nanoparticles were prepared in the same way as described 212 
previously but in the absence of thiamine. These nanoparticles were identified as NP.  213 
The second procedure, using the GT previously synthesized, was based on a controlled 214 
desolvation of the conjugate (dissolved in acetone) with water and subsequent 215 
stabilization with calcium. For this purpose, 400 mg GT were dissolved in 20 mL acetone 216 
and nanoparticles were obtained by the addition of 40 mL purified water containing 1.6 217 
mg calcium chloride. Acetone was eliminated under reduced pressure in a BÜCHI R-144 218 
apparatus (BÜCHI Labortechnik AG, Flawil, Switzerland) and purified by centrifugation 219 
at 5000 × g for 20 min (SIGMA Lab. centrifuges, Osterode am Harz, Germany) using 220 
dialysis tubes Vivaspin® 300,000 MWCO (Sartorius AG, Madrid, Spain). Finally, 800 mg 221 
lactose dissolved in 40 mL deionized water were added to the pellet and vortexed for 5 222 
minutes. The resulting suspension was dried by spray-drying using the same conditions 223 
as described above. These nanoparticles based on GT were identified as T-NPB. 224 
 225 
2.5. Preparation of fluorescently labeled nanoparticles 226 
In all cases, for the fluorescent labeling of nanoparticles, 2 mg Lumogen® F Red 305 were 227 
dissolved in the solution of acetone containing the polymer (Gantrez® AN or GT) prior 228 
the formation of the nanoparticles as described above. In a similar way, the resulting 229 
nanoparticles were purified and dried as aforementioned. 230 
 231 
2.6. Physico-chemical characterization of nanoparticles 232 
2.6.1. Size, zeta potential and surface morphology analysis 233 
The mean size and the zeta potential of freeze-dried nanoparticles were determined by 234 
photon correlation spectroscopy (PCS) and electrophoretic laser Doppler anemometry, 235 
respectively, using a Zetaplus apparatus (Brookhaven Instruments Corporation, 236 
Holtsville, USA).  In all cases, the size was measured after dispersion of nanoparticles in 237 
water whereas the zeta potential was quantified in KCl 0.1 M. 238 
The shape and morphology of nanoparticles were examined by scanning electron 239 
microscopy (SEM). For this purpose, the powder collected from the spray-drier was 240 
dispersed in water and centrifuged at 27,000 × g for 20 min. Then, the pellets were 241 
mounted on TEM grids, dried and coated with a palladium-gold layer using a Quorum 242 
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Technologies Q150R S sputter-coater (Ontario, Canada). SEM was performed using a 243 
ZEISS model “Ultra Plus” (Oberkochen, Germany) and LEO 435VP (ZEISS, Cambridge, 244 
United Kingdom) high resolution scanning electron microscope.  245 
2.6.2. Thiamine quantification 246 
Thiamine (vitamin B1) was quantified in the supernatants obtained during the 247 
purification step of nanoparticles by the chromatographic method described above. The 248 
standard curves were prepared in supernatant of non-loaded nanoparticles (R2>0.999). 249 
For analysis, samples of 1 mL from the supernatants were transferred to auto-sampler 250 
vials, capped and placed in the HPLC auto-sampler. Then, 10 µL aliquot was injected onto 251 
the HPLC column. Finally, the amount of thiamine associated to the nanoparticles was 252 
calculated as the difference between the initial amount of thiamine added and the 253 
amount of thiamine recovered in the supernatants by HPLC. 254 
 255 
2.7. Quantification of Lumogen® F red 305 256 
The amount of Lumogen® F red 305 loaded in the nanoparticles was quantified by UV-257 
Vis spectrometry at wavelength 573 nm (Labsystems iEMS Reader MF, Vantaa, Finland). 258 
For this purpose, 10 mg of the formulations were resuspended in 3 mL water and 259 
centrifuged at 41,410 x g for 20 min. Pellets were dissolved in 10 mL acetonitrile 75%. 260 
These solutions were finally diluted 1:10 in pure acetonitrile before the analysis. 261 
Standard curves were designed over the range of 10-35 µg/mL (R2≥0.990) from a 262 
Lumogen® F red 305 solution in acetonitrile 75% and were prepared in supernatant of 263 
non-loaded nanoparticles. Prior the use of fluorescently labelled nanoparticles for in 264 
vivo studies, the stability of the marker in the nanoparticles was assessed by incubation 265 
in simulated gastric (pH 1.2, 2 h) and intestinal (pH 6.8, 8 h) fluids. 266 
 267 
2.8. Mucin purification from porcine mucus 268 
Pig small intestines were obtained from a local abattoir immediately after slaughter and 269 
transported on ice to the laboratory. Sections of the intestines that did not visibly 270 
contain chyme were cut into 15 cm lengths and mucus was removed. To remove the 271 
mucus gentle pressure was applied to one end of the length with the fingers and 272 
continuously applied unidirectionally to the opposite end. Mucus gel  was added to a 273 
cocktail of enzyme inhibitors in phosphate buffer, pH 6.8 (Taylor et al., 2004). The mucin 274 
was purified following the protocol described by  (Taylor et al., 2004), with the addition 275 
of a second cesium chloride gradient to further remove cellular debris from the 276 
glycoprotein component of mucus. All freeze dried samples were stored at -20 °C until 277 
used. 278 
 279 
2.9. Pulsed-Gradient Spin-Echo NMR assessment of mucin mobility  280 
In order to evaluate the slippery capacities of nanoparticles, the diffusion of intestinal 281 
pig mucin in presence of these nanocarriers was evaluated by pulsed-gradient spin-echo 282 
NMR (PGSE-NMR). Measurements were performed on a Bruker DMX400 NMR 283 
spectrometer operating at 400 MHz (1H) using a stimulated echo sequence (Callaghan, 284 
1991). All the experiments were run at 37 °C using the standard heating/cooling system 285 
of the spectrometer to an accuracy of ± 0.3 °C.  286 
Generally, the proton NMR spectrum - a series of peaks located at characteristic values, 287 
the so-called chemical shifts measured in ppm - is recorded from the solution with 288 
increasing intensity of the pulsed-gradients. The self-diffusion coefficient, D, is deduced 289 
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by fitting the attenuation (decay) of the integral for a chosen peak to Eq. 1 as a function 290 
of the characteristics of the gradient pulses,  291 𝐴 (𝛿, 𝐺, ∆) = 𝐴0exp [−k𝐷]               [Equation 1] 292 
where 𝐴 is the signal intensity and k = 𝛾2𝐺2𝛿2 (∆ − 𝛿/3 ), given 𝛾 is the magnetogyric 293 
ration, ∆ the diffusion time, 𝛿 the gradient pulse length, and 𝐺 is the gradient field 294 
strength. The gradient pulses are ramped to their desired value over a ramp time, σ, 295 
typically 250 µs.  296 
 297 
For complex spectra such as those encountered here where the observed peaks may 298 
arise from different components within the system, or there may be a range of diffusing 299 
rates, the diffusion data are better analyzed by fitting to this Eq. 1 the entire spectrum 300 
using “CORE”, a program devised to resolve the various components present in such 301 
data (Stilbs et al., 1996). CORE evaluates the experimental data in two levels, yielding 302 
not only estimates of the diffusion coefficients for each component in the sample but 303 
also their relative intensities enabling a more insightful analysis of complex datasets.  304 
For the mucin diffusion coefficient measurement, the nanoparticles were dispersed in 305 
deuterated water (0.5%, w/v) as described before (Pereira de Sousa et al., 2015a). Then, 306 
the nanoparticles suspensions were added into an intestinal mucin solution (5% w/v) 307 
also in deuterated water and left to equilibrate for 24 h. Finally, 0.6 mL was transferred 308 
to 5 mm o.d. Wilmad NMR tubes (Sigma–Aldrich, Haverhill, UK). 309 
 310 
2.10. Labelling of nanoparticles with 99mTc 311 
Nanoparticles were labelled with technetium-99m by reduction with stannous chloride 312 
as described previously (Areses et al., 2011). Briefly, 1-2 mCi of freshly eluted 99mTc-313 
pertechnetate was reduced with 0.03 mg/mL stannous chloride and the pH was adjusted 314 
to 4 with 0.1N HCl. Then, an amount of dried powder containing 2 mg nanoparticles 315 
were dispersed in 1 mL water prior the addition of the reduced 99mTc. The mixture was 316 
vortexed for 30 s and incubated at room temperature for 10 min. The overall procedure 317 
was carried out in helium-purged vials. The radiochemical purity was examined by paper 318 
chromatography (Whatman 3MM) developed with NaCl 0.9%. The labelling yield was 319 
always over 90%. 320 
 321 
2.11. Gastro-intestinal transit studies with radio labelled nanoparticles 322 
These studies were carried out in male Wistar rats weighing 250–300 g that had fasted 323 
for 12 h with free access to water. All the procedures were performed following a 324 
protocol previously approved by the “Ethical and Biosafety Committee for Research on 325 
Animals” at the University of Navarra in line with the European legislation on animal 326 
experiments. Animals were briefly stunned with 2% isoflurane gas (flow of oxygen of 0.2 327 
L/min) for administration of nanoparticles (above 1 mL) by oral gavage, and then quickly 328 
awakened. Each animal received one single dose of radiolabelled nanoparticles (1 mCi; 329 
0.8-1.0 mg of radiolabelled nanoparticles that were completed with up to 10 mg with 330 
unlabelled NP). Three hours after administration of NP, animals were anaesthetised with 331 
2% isoflurane gas (flow of oxygen of 0.2 L/min) and placed in prone position on the 332 
gammacamera (Symbia T2 Truepoint; Siemens Medical System, Malvern, USA). SPECT-333 
CT images were acquired for 25 min, with the following parameters for  SPECT: 128 x 334 
128 matrix, 90 images, 7 images per second and CT: 110 mAs and 130 Kv, 130 images, 335 
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slice thickness 3 mm Fused images were processed using the Syngo MI Applications 336 
TrueD software.   337 
 338 
2.12. In vivo evaluation of the mucus permeating properties of nanoparticles 339 
These studies were carried out using a protocol described previously (Salman et al., 340 
2007) with minor modifications, after approval by the responsible Committee by the 341 
University of Navarra (Ethical and Biosafety Committee for Research on Animals). 342 
Briefly, male Wistar rats (average weight 225 g; Harlan, Barcelona, Spain) were placed 343 
in metabolic cages and fasted overnight but with free access to water. All animals 344 
received orally 25 mg of fluorescently labeled nanoparticles dispersed in 1 mL water. At 345 
different times, animals were sacrificed. The abdominal cavity was opened in order to 346 
remove the stomach and small intestine, which were removed and carefully rinsed with 347 
PBS in order to eliminate the fraction of nanoparticles remaining in the lumen. Then, 348 
both the stomach and the small intestine were cut into small portions to facilitate their 349 
digestion with NaOH 3M for 24 h and the resulting residues were treated with methanol 350 
and centrifuged. Finally, aliquots of the supernatants were assayed for Lumogen® F Red 351 
305 content by spectrofluorimetry (TECAN, Grödig, Austria) at lex 485 nm and lem 540 352 
nm.  353 
Finally, the tissue distribution of nanoparticles in the gastrointestinal mucosa was 354 
visualized by fluorescence microscopy. For that purpose, 25 mg of Lumogen® F Red-355 
labeled nanoparticles were orally administered to rats as described above. Two hours 356 
later, animals were sacrificed by cervical dislocation and the guts were removed. Ileum 357 
portions of 1 cm were collected, cleaned with PBS, stored in the tissue proceeding 358 
medium O.C.T. and frozen at -80°C. Each portion was then cut into 5-µm sections on a 359 
cryostat and attached to glass slides. Finally, these samples were fixed with 360 
formaldehyde and incubated with DAPI (4’,6-diamidino-2-phenylindole) for 15 minutes 361 
before the cover assembly. The presence of both fluorescently loaded poly(anhydride) 362 
nanoparticles in the intestinal mucosa and the cell nuclei dyed with DAPI were visualized 363 
in a fluorescence microscope (Axioimager M1, Zeiss, Oberkochen, Germany) with a 364 
coupled camera (Axiocam ICc3, Zeiss, Oberkochen, Germany) and fluorescent source 365 
(HBO 100, Zeiss, Oberkochen, Germany). The images were captured with the software 366 
ZEN (Zeiss, Oberkochen, Germany). 367 
 368 
2.13. Statistical analysis 369 
The in vivo data were compared using a one way analisys of the variance (ANOVA) 370 
followed by a Tukey-Kremer multicomparison test, using the NCSS 11 statistical software 371 
(Kaysville, US). The difference was considered as significant when P<0.05 or p<0.001. 372 
 373 
3. Results 374 
3.1. Characterization of Gantrez-thiamine conjugates (GT) 375 
The infrared spectroscopy study of the conjugates (Figure 1) showed the formation of a 376 
new binding at ~1650 cm-1 associated with the stretching of the new amide group v(C=O) 377 
originated as a result of the amine group of the thiamine and the anhydride groups of 378 
Gantrez ® AN 119. Besides, the GT spectrum showed a weak band at ~1352 cm-1 379 
corresponding to C-N vibrations of thiamine residues (Ferrari et al., 2003).  380 
Regarding elemental analysis (Table 1), the binding of thiamine to the polymer backbone 381 
slightly decreased the percentage of carbon, whereas the hydrogen content increased. 382 
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On the other hand, the titration of the hydrated polymer and conjugates confirmed a 383 
reduction in the amount of free carboxylic groups by the binding of thiamine to Gantrez® 384 
AN (Table 1). In fact, under the experimental conditions used here, about 13% of the 385 
maleic anhydride groups of Gantrez® AN were used for the covalent binding of thiamine, 386 
generating (from each reactant anhydride group) an amide bond with vitamin B1 and 387 
one carboxylic acid residue. In other words, the % of substitution would be of 13%. By 388 
HPLC, the amount of thiamine associated to the poly(anhydride) backbone was 389 
calculated to be 8.7 µg/mg. Finally, with this data, the MW of the conjugate (GT) was 390 
96.33 kDa. 391 
 392 
3.2. Preparation of thiamine-coated nanoparticles 393 
Thiamine coated nanoparticles were prepared following two different preparative 394 
processes. The first method consisted on the preparation of Gantrez® AN nanoparticles 395 
(NP or “naked” poly(anhydride) nanoparticles) followed by a thiamine coating 396 
procedure (T-NPA). The second method consisted on the preparation of nanoparticles 397 
from a Gantrez® AN-thiamine conjugate previously synthetized (T-NPB). Table 2 shows 398 
the main physico-chemical properties of the resulting nanoparticles. In all cases, the 399 
different nanoparticle formulations displayed a mean size of about 210-230 nm and a 400 
negative zeta potential. However, the negative surface charge was slightly lower for 401 
thiamine coated nanoparticles (T-NPB), but not statistically significative, than for 402 
nanoparticles obtained from the GT (T-NPA) and the “naked” nanoparticles (NP). 403 
Interestingly, both preparative procedures produced homogeneous batches of 404 
nanoparticles (PDI lower than 0.2) and high yields close to 97.5%. For T-NPA, the amount 405 
of thiamine associated to the nanoparticles was 15 µg/mg. Finally, the amount of 406 
Lumogen® F Red 305 incorporated into the nanoparticles was calculated to be similar for 407 
all the formulations tested and close to 0.7 µg/mg (data not shown).  408 
Figure 2 shows the morphological analysis of the different nanoparticle formulations. 409 
This analysis by SEM confirmed that all batches of nanoparticles consisted of 410 
homogeneous populations of spherical particles. NP presented a smoother surface than 411 
thiamine-coated nanoparticles and T-NPB. In addition, T-NPA appeared to be slightly 412 
rougher than T-NPB. 413 
 414 
3.3. In vitro evaluation of the mucus penetrating properties of nanoparticles 415 
PGSE-NMR is a non-invasive technique that allows determination of the diffusive 416 
character of mucin gel and changes in that dynamic property on addition of selected 417 
polymer nanoparticles. The diffusion coefficient is measured from the decrease in 418 
intensity of the peaks in the NMR spectrum, a rapidly decaying signal corresponds to 419 
high mobility quantified in terms of a large diffusion coefficient (Figure 3).  420 
In complex systems such as those being examined here, it is quite common for the data 421 
to show more than one diffusive rate. These may arise due to the presence of several 422 
components that each shows peaks at the same chemical shift (so-called overlapping 423 
spectra) or that particular component being present in different physical environments, 424 
e.g. gelled or non-gelled materials. Under those circumstances, it is first useful to 425 
consider an average diffusion coefficient, being the signal intensity-weighted value of 426 
the other discrete values, Table 3, when the different nanoparticle formulations used in 427 
this study have been added to the mucin samples. Analysing the ratio of the mean 428 
diffusion coefficients i.e. the mucin plus NP value divided by the value from the mucin-429 
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only sample, shows that the mucin diffusion was largely unchanged for the control 430 
particle (row “NP”). On the contrary, the ratio of the weighted mucin diffusion 431 
coefficients increased a factor of 5-fold when both thiamine decorated nanoparticles 432 
were incubated with mucin, addition of the nanoparticles increased the dynamics of the 433 
mucin. 434 
Focusing on the detail within the analysis, the entire PGSE-NMR spectra for mucin alone 435 
fitted best to two diffusive rates, (Figure 3A), with peaks occurring at similar chemical 436 
shifts for both components i.e. the same material. The most straightforward 437 
interpretation would be that the gelled fraction of the mucin (sometimes called “firm”) 438 
corresponds to the slower diffusing component, (Dslow= 2.1 E-13 m2/s), representing 21% 439 
of the signal, whereas the faster term - the greater component - is the non-gelled 440 
fraction (Dfast= 8.3E-12 m2/s; 79% of the signal). Interestingly, when nanoparticles were 441 
added to the mucin sample, a third much slower diffusive rate appeared (Figure 3B), 442 
respect to the other two components, indicating modification of the structure of the 443 
mucin gel. This modification decreases the mobility of some of the mucin but 444 
significantly increases the mobility of another portion. Notwithstanding the emergence 445 
of this slow component, the diffusion of the bulk of the mucin increased (Table 3, 446 
columns D2 and D3), with the principle component and the average value some 4-5x 447 
times higher for thiamine decorated nanoparticles than for the naked poly(anhydride) 448 
nanoparticles. 449 
 450 
3.4. Biodistribution studies with 99mTc radiolabelled nanoparticles 451 
Figure 4 shows the comparison of the biodistribution of nanoparticles (after 452 
radiolabelling with 99mTc) when administered by the oral route to laboratory animals. In 453 
all cases, 2 hours post-administration, nanoparticles were visualized in the stomach and 454 
the small intestine of animals. However, the intensity of the radioactivity in the stomach 455 
of animals was higher for NP than for T-NPA and T-NPB. On the contrary, nanoparticles 456 
containing thiamine appeared to move faster than NP because the radioactivity was 457 
more intense in the small intestine than in the stomach of animals. Interestingly, no 458 
activity was observed in the liver or the lungs of the animals.  459 
 460 
3.5. Evaluation of the mucus permeating properties of nanoparticles 461 
Figure 5 shows the evaluation of the interaction of nanoparticles with the surface of the 462 
stomach mucosa and the small intestine expressed as the adhered fraction of the given 463 
dose. In all cases the animals received a dose of 25 mg of nanoparticles dispersed in 1 464 
mL water. Two hours post-administration (Figure 5A), significant differences were found 465 
between control nanoparticles (NP), which displayed a significantly higher capability to 466 
interact with the stomach mucosa than nanoparticles containing thiamine (p<0.05). 467 
Actually, the fraction of the given dose in close contact with the stomach mucosa was 468 
almost 3-fold higher than T-NPA and almost 14-fold higher than for T-NPB.  469 
Interestingly, in the small intestine, the capability of NP to interact with the mucosa was 470 
significantly lower than for nanoparticles containing thiamine. In fact, both T-NPA and 471 
T-NPB presented a strong capability to remain close contact with the surface of the small 472 
intestine (mainly in the I2 segment corresponding with the distal jejunum and proximal 473 
ileum). Thus, for both types of nanoparticles, more than 30% of the given dose was 474 
found in close contact with the surface of the mucosa, compared with a 13.5% in the 475 
case of NP. 476 
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Four hours post-administration (Figure 5B), the remained fraction of NP in close contact 477 
with the gut mucosa was very low. Only a small amount was quantified in the distal 478 
region of the ileum and caecum. On the contrary, for T-NPA and T-NPB, about 35% of 479 
the given dose was mainly localized in the ileum of animals (segments I2 and I3). Overall, 480 
no significant differences in the distribution of T-NPA and T-NPB were observed. 481 
However, if any, T-NPB appeared to move faster than T-NPA. 482 
Figure 6 shows fluorescence microscopy images of ileum samples from the animals 483 
treated with Lumogen® F Red-labelled nanoparticles. NP displayed a localisation mainly 484 
restricted to the mucus layer protecting the epithelium both in the stomach (Figure 6A) 485 
and in the ileum (Figures 6B and 6C).  On the contrary, for nanoparticles containing 486 
thiamine it was evident that these carriers were capable of reaching the epithelium and 487 
interact broadly with the intestinal cells (Figures 6E, 6F, 6H and 6I).  488 
 489 
4. Discussion  490 
In this work, the effect of the preparative process of thiamine-coated nanoparticles on 491 
their distribution within the gut (after oral administration) was evaluated. For this 492 
purpose, two different procedures for the preparation of these nanocarriers were 493 
compared.  494 
In the former, a conventional bottom-up procedure with two consecutive steps was 495 
employed (Salman et al., 2007). In this approach, the copolymer of methyl vinyl ether 496 
and maleic anhydride (Gantrez® AN) was initially transformed into poly(anhydride) 497 
nanoparticles and, subsequently, functionalized with thiamine before purification and 498 
drying. With this approach, the resulting thiamine-coated nanoparticles (T-NPA) 499 
displayed a mean size of about 215 nm and a negative zeta potential of –38 mV (Table 500 
2). These physico-chemical characteristics were quite similar to that observed for bare 501 
nanoparticles (NP); although T-NPA, when observed by SEM (Figure 2A), displayed a 502 
rougher surface than NP. In addition, the amount of thiamine associated with T-NPA 503 
nanoparticles was about 15 µg/mg with a surface density (dT) of about 0.98 molecules 504 
per nm2. In spite of its simplicity, this typical approach may be not the most adequate 505 
when biologically active compounds of hydrophilic nature (e.g., therapeutic peptides 506 
and proteins) have to be encapsulated into these nanoparticles. In fact, during the 507 
functionalization process, a significant fraction of the encapsulated compound may be 508 
lost due to a premature release in the medium in which the binding takes place (Dalwadi 509 
et al., 2005; Patil et al., 2009; Tang et al., 2009). This migration of the loaded compound 510 
(from the nanoparticle matrix through the external medium) may also affect the surface 511 
properties of the resulting nanoparticles and, thus, their behaviour in vivo.  512 
In the latter, the first step was to build a conjugate (between Gantrez® AN and thiamine) 513 
to be used as material for the preparation of the functionalized nanoparticles. 514 
Nanoparticles from GT were obtained by forming calcium ion bridges between 515 
neighbouring carboxylic acid groups of the polymer backbone. The presence of calcium 516 
was necessary to confer stability to the resulting nanoparticles. This strategy is more 517 
time-demanding due to the necessary synthesis of the pre-cursor. However, the 518 
subsequent preparation step to form the nanoparticles is simpler and shorter, 519 
minimizing the negative effects on the payload.  520 
In our case, the synthesized conjugate between Gantrez® AN and vitamin B1 contained 521 
about 9 µg thiamine per mg, with a substitution degree of 13%. From this polymer 522 
conjugate, the resulting nanoparticles (T-NPB) displayed a slightly higher mean size (227 523 
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vs 215 nm, Table 2) and a lower negative zeta potential (-30 vs -38 mV, Table 2) than T-524 
NPA. By SEM, T-NPB presented a similarly rough surface as did T-NPA (Figure 2B and 2C). 525 
However the main concern by using the Gantrez® AN-thiamine conjugate was the 526 
impossibility of precisely determined the number of thiamine molecules on the surface 527 
of the resulting nanoparticles (T-NPB). For other types of hydrophilic conjugates, such 528 
as copolymers between polyesters and poly(ethylene glycol) (e.g. PLGA-PEG), it has been 529 
confirmed that during the formation of nanoparticles the polyester chains form the core, 530 
while PEG chains are oriented to the water phase (Li et al., 2001; Schubert et al., 2011). 531 
In our case, it is plausible to imagine that the hydrophilic residues of thiamine would be 532 
mainly exposed on the surface of nanoparticles. In order to confirm this hypothesis, the 533 
mucus penetrating properties of nanoparticles as well as their fate in vivo was studied. 534 
When T-NPA or T-NPB were orally administered to rats, they distributed along the 535 
gastrointestinal tract (Figure 4) with a lower tendency to concentrate in the stomach of 536 
animals than bare nanoparticles. This observation was corroborated by the 537 
measurement of the fluorescence marker associated with the nanoparticles in different 538 
gut sections (Figure 5). Thus, 2 h post-administration, about 15% of the given dose of NP 539 
was quantified in contact with the stomach mucosa. This value represented at least 3-540 
times greater dose than for T-NPA or T-NPB. On the contrary, the amounts of T-NPA or 541 
T-NPB adhered to the small intestine mucosa (mainly in the distal jejunum and proximal 542 
ileum, I2 segment in Figure 5A) were significantly higher than for NP (p<0.001). Four 543 
hours post-administration, the amount of bare nanoparticles adhered to the gut mucosa 544 
was very low, whereas, for T-NPA and T-NPB, the fraction of the given dose in close 545 
contact with the small intestine mucosa remained higher than 30%. These observations 546 
are in line with our previous results in which the coating of poly(anhydride) 547 
nanoparticles with thiamine (T-NPA) increased 3-fold the capability of these 548 
nanocarriers to develop adhesive interactions within the gut and, at the same time, 549 
decreased their elimination rate from the mucosa (Salman et al., 2007). In addition, from 550 
a microscopic point of view (Figure 6), it was clear that bare nanoparticles displayed a 551 
different behaviour than thiamine-nanoparticles (T-NPA and T-NPB). Thus, within the 552 
gut mucosa, NP was localized in the protective mucus layer confirming their 553 
mucoadhesive capability (Arbós et al., 2002; Gamazo et al., 2015). On the contrary, 554 
thiamine nanoparticles appeared to be capable of reaching the intestinal epithelium, 555 
confirming their mucus permeating properties. These results agree well with those 556 
obtained from the in vitro evaluation of the diffusion of the intestinal mucin by PGSE-557 
NMR (Figure 3, Table 3). Interestingly, the diffusion coefficient of intestinal mucin was 558 
not affected when bare nanoparticles were added. However, when incubated with T-559 
NPA or T-NPB, there was a significant increase in the diffusion coefficient of the mucin 560 
(about 5-fold). These differences can only be attributed to the presence of thiamine on 561 
the surface of nanoparticles that would transform their surface, conferring slippery 562 
properties and facilitating their permeability through a mucus gel layer. It is also worth 563 
noting that the mucin alone, and due to its heterogeneous composition, fitted well to 564 
two diffusion coefficients, as described previously (Pereira de Sousa et al., 2015a): 565 
Dfast=8.3E-12 m2/s, 21% of the signal, Dslow= 2.1 E-13 m2/s, 79% of the signal. 566 
On the other hand, when nanoparticles were added to the mucin samples the spectra 567 
fitted best to 3 diffusion coefficients indicating that poly(anhydride) nanoparticles 568 
possess a hydrophobic surface and one could imagine a strong interaction with the 569 
hydrophobic portions of the mucin molecule, which would lead to a mucoadhesive 570 
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property and presumably a viscosification of the sample as the particles act as nodes for 571 
the enhancement of the mucin gel cross-linking. However, the polymer backbone 572 
forming the thiamine decorated nanoparticles has a highly dense coat of the low MW 573 
and highly hydrophilic compound, thiamine, which one assumes will prevent an 574 
interaction with the mucin network. 575 
 576 
5. Conclusion 577 
In summary, the mucoadhesive poly(anhydride) nanoparticles were transformed into 578 
mucus-penetrating ones by their coating with vitamin B1. These thiamine-nanoparticles 579 
displayed a high ability to diffuse and cross through the protective mucus layer in order 580 
to reach the intestinal epithelium. Interestingly, thiamine-decorated nanoparticles may 581 
be prepared by two different procedures. Both approaches yield nanocarriers with 582 
similar physico-chemical and biodistribution properties. This result increases the 583 
versatility of such nanocarriers as oral delivery systems for a number of biologically 584 
active compounds.  585 
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Figure Captions 705 
Figure 1. Confirmation of GT conjugate. (A) Schematic representation of the formation 706 
of the new conjugate. (B) IR spectra of Gantrez® AN polymer (G) and Gantrez® AN-707 
thiamine conjugate (GT).  708 
 709 
Figure 2. Scanning electron microphotographs of “naked” poly(anhydride) nanoparticles 710 
(A), T-NPA (B) and T-NPB (C). In the above right side, a magnification of a section of each 711 
microphotograph is shown.  712 
 713 
Figure 3. PGSE-NMR spectra of mucin alone (A3) obtained from the two components 714 
forming the gel (A1-A2) and mucin in the presence of nanoparticles (B4) obtained from 715 
the three components forming the gel (B1-B3). x axis: frequency; y axis: intensity and z 716 
axis: trace. 717 
 718 
Figure 4. Volume rendered fused SPECT-CT images from representative animals 2 h after 719 
administration of 99mTc-labelled NP by oral gavage. NP: “naked” nanoparticles; T-NPA: 720 
thiamine-coated poly(anhydride) nanoparticles; T-NPB: Gantrez® AN-thiamine 721 
nanoparticles. 722 
 723 
Figure 5. Percentage of the given dose in close contact with the mucosa of the different 724 
parts of the gastrointestinal tract. (A) Two-hours and (B) 4-hours post-administration. 725 
NP: “naked” nanoparticles; T-NPA: thiamine-coated poly(anhydride) nanoparticles; T-726 
NPB: Gantrez® AN-thiamine nanoparticles (n=3).  STO : stomach ; I1, I2, I3 : small 727 
intestine portions ; CE : caecum. 728 
 729 
Figure 6. Fluorescence microscopic visualisation of nanoparticles containing thiamine (T-730 
NPA and T-NPB) and control ones (NP) in a longitudinal section of the stomach mucosa 731 
and ileum of rats 2 hours post administration. A: NP in the stomach mucosa; B and C: NP 732 
in the ileum mucosa; D: T-NPA in the stomach; E and F: T-NPA in the ileum mucosa; G: 733 
T-NPB in the stomach mucosa; H and I: T-NPB in the ileum mucosa.  734 
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 759 
Table 1. Physico-chemical characterization of Gantrez® AN and its conjugate with 760 
thiamine (GT). For titration and HPLC experiments, data expressed as mean ± SD (n=3).  761 
 762 
Polymer C% H% O% % Free -
COOH 
DS (%) MW 
(kDa) 
Thiamine content 
(µg/mg G) 
G 53.49 5.18 41.33 100 ± 0 0 95.50 - 
GT 53.19 5.58 41.23 87 ± 1 13 96.33 8.7 ± 0.6 
 763 
 764 
 765 
Table 2. Physico-chemical characterization of nanoparticles. NP: “naked” 766 
poly(anhydride) nanoparticles; T-NPA: poly(anhydride) nanoparticles coated with 767 
thiamine; T-NPB: Gantrez® AN-thiamine conjugate nanoparticles. Data expressed as 768 
mean ± SD (n=3). 769 
 770 
Formulation Size (nm) PDI Zeta Potential 
(mV) 
Thiamine 
(µg/mg NP) 
NP 213 ± 4 0.031 ± 0.012 -36.2 ± 3.0 - 
T-NPA 215 ± 3 0.128 ± 0.023 -38.5 ± 3.2 15 ± 0.6 
T-NPB 227 ± 5 0.092 ± 0.020 -30.6 ± 5.4 ND 
 771 
 772 
Table 3. Diffusion coefficients of the mucin in the presence of nanoparticles. The 773 
experiments were carried out with intestinal mucin. D1-D3: diffusion coefficients of the 774 
components forming the mucin. D: diffusion coefficient; R: Ratio between the diffusion 775 
coefficients obtained for the nanoparticle formulation and mucin. Intensities of the 776 
diffusion coefficients of each component in brackets.  777 
 778 
Formulation D1 
(/1011 m2 s-1) 
D2 
(/1011 m2 s-1) 
D3 
(/1011 m2 s-1) 
Dweighted 
(/1011 m2 s-1) 
R 
 
Mucin - 0.021 (21%) 0.830 (79%) 0.66 1.0 
NP 0.002 (21%) 0.051 (16%) 1.200 (63%) 0.79 1.2 
T-NPA 0.002 (11%) 0.249 (18%) 4.591 (71%) 3.29 5.0 
T-NPB 0.004 (14%) 0.391 (22%) 4.780 (64%) 3.12 4.7 
 779 
 780 
 781 
 782 
 783 
